|
|
|
|
| Advertisement |
 |
Deloitte's 2019 Life Sciences accounting and financial reporting update
Insights on new accounting standards and more
A year of major change for life sciences companies is underway. Deloitte's latest update on life sciences financial reporting explains what accounting departments need to know to keep up in a rapidly evolving environment.
 Download the full report here
|
|
|
ADVERTISEMENT
|
|
| Advertisement |
The Future of Selling Healthcare: An approach to disruptive change
Pharmaceutical sales leaders can no longer just think about how many reps they need and how to structure their sales forces by product and franchise. Instead, we need to reconsider not only how we evolve the role of the rep, but how we define work, how our teams work together, and how we manage, which will, in aggregate, redefine the future of selling. This e-book provides a detailed analysis that describes how and why organizations must adapt to disruptive changes.
 Download eBook
|
|
| Global |
|
|
| Special Feature |
 |
|
Pharm Exec's Top 50 Companies 2019 |
Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market
… /Read More/ |
|
|
|
| Industry update |
| //RefleXionTM Medical (Hayward, CA) announced that Thorsten Melcher, Ph.D., has joined as Chief Business Officer.
//
Mereo BioPharma (London, UK and Redwood City, CA) announced the
appointment of Richard Francis as Head of Pharmaceutical Development, effective August 1, 2019.
//
Exactus (Delray Beach, FL) appointed Kenneth E. Puzder as Chief Financial Officer.
//
Aptinyx (Evanston, IL) announced that Joseph Moskal, Ph.D., the company's Chief Scientific Officer, is retiring to focus on his academic work at Northwestern University. Dr. Moskal will continue his close association with Aptinyx in a senior advisory capacity.
//
Soligenix (Princeton, NJ) recruited Diane L. Parks to its Board of Directors.
//
Ziopharm Oncology announced that the National Cancer Institute's Drew Deniger, Ph.D., has been appointed to lead the company's program to genetically modify T cells to express neoantigen-specific T-cell receptors, effective July 29, 2019.
//
Andrew Bast joined Greater Than One, a New York-based healthcare marketing agency, as Chief Strategy Officer.//
|
|
|
|
|
|
|
|
|
